Your dog was diagnosed with Cutaneous Lymphoma. Uncommon form of lymphoma. Epitheliotropic form (mycosis fungoides-like) is T-cell in origin and more common. Non-epitheliotropic form has better prognosis. Can mimic dermatologic conditions, causing diagnostic delay. NOTE: No dedicated clinical trials for canine cutaneous lymphoma were identified as of March 2026. This represents a genuinely underserved area of veterinary oncology research. The ORBIT trial (University of Minnesota) accepts aggressive lymphoma broadly but is not cutaneous-specific. Compare 4 treatment options for dogs including CCNU (Lomustine), Verdinexor (Laverdia-CA1), Isotretinoin (Retinoid Therapy) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Cutaneous Lymphoma
Canine Oncology Treatment Guide
Cutaneous Lymphoma
Round Cell
About This Cancer
Cutaneous lymphoma is an uncommon form of lymphoma that affects the skin rather than the internal lymph nodes. The most common type, called epitheliotropic lymphoma (similar to mycosis fungoides in humans), arises from T-lymphocytes that invade the outer layers of the skin. It typically progresses slowly at first, often mimicking common skin diseases such as dermatitis or allergies, which can delay diagnosis. As the disease advances, patches and plaques may develop into raised nodules and ulcers. A less common non-epitheliotropic form arises from B-lymphocytes and tends to have a somewhat better outlook. Cutaneous lymphoma is generally a chronic, progressive disease that is managed rather than cured, with treatments aimed at controlling symptoms and slowing progression.
Modified WHO Staging for Cutaneous Lymphoma
Staging based on extent of skin involvement, lymph node status, and systemic disease.
Prognostic Factors(1)
Minimum Workup(6 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.